communities also had a higher rate of loss of primary patency (36% vs 28%; P ¼ .04) and occlusion (21% vs 14%; P ¼ .003).
Objectives: Split-thickness skin grafting is a common and effective tool for lower extremity wound coverage among patients with peripheral vascular disease. However, many patients with lower extremity wounds also present with cardiovascular disease which mandates chronic antiplatelet or anticoagulant therapy. This may discourage some surgeons from using split thickness skin grafting in the management of lower extremity wounds. Additionally, some surgeons may advocate temporary cessation of chronic antiplatelet therapy to reduce the risk of hematoma formation and improve skin graft take which puts the patient at significant cardiovascular risk. Our hypothesis is that these medications do not affect graft take and wound healing.
Methods: To examine these questions the medical records of all patients receiving split thickness skin grafting for lower extremity wounds from 2014 to 2016 were examined with a successful graft defined as >99.5% wound coverage at 30 days.
Results: There were 231 wounds identified among 192 patients; 124 patients were receiving an antiplatelet or anticoagulant therapy at the time of grafting. Of these patients 14 received low-molecularweight heparin (LMWH), 19 received warfarin, 18 received a novel Xa inhibitor (Xai), 32 received clopidogrel, and 89 received aspirin. Three hematomas were reported during the first 30 days of follow-up one patient was receiving no antiplatelet or anticoagulant therapy, one patient was on LMWH, and one patient was receiving aspirin and a Xai. Patients receiving an antiplatelet or anticoagulant agent had no difference in outcome when compared with patient not receiving one of these agents (P > .05). Additionally, patients who continued their antiplatelet agent had no significant difference in outcome when compared with patients whose antiplatelet agent was stopped before grafting.
Conclusions: These data suggest there is no increased risk of graft failure while receiving an anticoagulant or antiplatelet agent. Patients who are appropriate for split-thickness skin grafting should proceed without cessation of anticoagulation or antiplatelet therapy.
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A Objectives: Surgical site infections (SSIs) are one of the leading causes of thirty-day readmissions following vascular surgery, add to patient morbidity, and increase cost. The reported incidence of SSIs following vascular surgery ranges from 2% to 30% and is higher than many other "clean" procedures. The rate of SSIs following lower extremity vascular surgery at our institution was well above the national benchmark of 7% to 10%. This prompted development and implementation of a comprehensive quality improvement initiative (QII) initiative to reduce SSIs. This study analyzes and compares preoperative, intraoperative and postoperative factors previously identified as predictors of SSIs before and after the implementation of our QII.
Methods: The vascular surgery department at our institution developed a change in clinical practice in all aspects of the care of the vascular surgery patient as a QII to reduce the incidence of SSIs. After performing a literature review and identifying factors linked to SSIs, we developed protocols and provided education to physicians and ancillary staff regarding these goals of care. We then developed a retrospective database of all vascular bypass surgeries involving an infrainguinal incision in the 12-month periods before and after introduction of our initiative to identify factors most influential in reducing SSIs.
Results: During the study period 294 patients met the inclusion criteria. The percentage of patients with development of SSI decreased postimplementation (5% vs 13% pre-implementation; P ¼ .0217). In comparing pre-implementation and postimplementation of our initiative, there were significant differences in the following: histories of insulin dependent diabetes mellitus (DM), cardiovascular accident (CVA), claudication, tissue loss, or trauma as indication for procedure; long duration of procedure, stapled wound closure; preoperative hair removal, preoperative/postoperative bactroban, preoperative antibiotics, recommended antibiotics dosage change, use of postoperative order set, discharge with anticoagulants and discharge with home health. In comparing development of SSI versus no SSI, after adjusting for implementation (pre-initiative and postinitiative) accordingly, the following risk factors were found to be significant: diabetes mellitus (odds ratio [OR], 7.061; 95% confidence interval [CI], 2.805-17.774); readmission within 30 days from surgery (OR, 14.787; 95% CI, ; gender female at higher risk (OR, 3.064; 95% CI, 1.353-6.938); and preoperative hair removal (OR, 0.251; 95% CI, 0.087-0.726). Change in recommended preoperative antibiotics also led to decrease in SSI, although not statistically significant.
Conclusions: Implementation of a comprehensive QII, increased awareness, and education of physicians and ancillary staff led to a significant reduction in the incidence of SSIs.
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